Trial Profile

A clinical trial assessing OPGx 003

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPGx 003 (Primary)
Indications Leber congenital amaurosis
Focus Adverse reactions; Therapeutic Use
Sponsors Opus Genetics

Most Recent Events

08 Sep 2022 New trial record
01 Sep 2022 According to Opus Genetics media release, the company hosts inaugural patient advocacy outreach webinar on Inherited Retinal Diseases, This webinar highlighted recent and upcoming milestones in this program, webinar can be viewed at Opus YouTube channel here: https://www.youtube.com/watch?v=mtFe8ZuFXmM.
01 Sep 2022 According to Opus Genetics media release, Opus plans to request a pre-IND meeting with the FDA in 2022 to inform next steps and timing of a clinical trial

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com